Eloralintide Phase 2 trial (NCT06230523)
A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 263
- actual
- Start
- 5 Feb 2024 (actual)
- Primary completion
- 30 May 2025 (actual)
- Sponsor
- Eli Lilly and Company
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo | Placebo comparator | Drug: Placebo | Participants received subcutaneous (SC) injections of eloralintide-matching placebo administered once weekly (QW) for 48 weeks. |
| 1 mg Eloralintide | Experimental | Drug: Eloralintide | Participants received eloralintide 1 milligram (mg) SC QW for 48 weeks. |
| 3 mg Eloralintide | Experimental | Drug: Eloralintide | Participants received eloralintide 3 mg SC QW for 48 weeks. |
| 6 mg Eloralintide | Experimental | Drug: Eloralintide | Participants received eloralintide 6 mg SC QW for 48 weeks. |
| 9 mg Eloralintide | Experimental | Drug: Eloralintide | Participants received eloralintide 9 mg SC QW for 48 weeks. |
| 6/9 mg Eloralintide | Experimental | Drug: Eloralintide | Participants received eloralintide 6 mg SC QW for 20 weeks, followed by eloralintide 9 mg SC QW for 28 weeks, for a total treatment duration of 48 weeks. |
| 3/6/9 mg Eloralintide | Experimental | Drug: Eloralintide | Participants received eloralintide 3 mg SC QW for 4 weeks, followed by eloralintide 6 mg SC QW for 4 weeks, followed by eloralintide 9 mg SC QW for 40 weeks, for a total treatment duration of 48 weeks. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight at Week 48 | Baseline, Week 48 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change From Baseline in Body Weight at Week 48 | Baseline, Week 48 |
| Mean Percentage of Participants Who Achieved Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline to Week 48 | Baseline to Week 48 |
| Mean Percentage of Participants Who Achieved ≥ 10% Body Weight Reduction From Baseline to Week 48 | Baseline to Week 48 |
| Change From Baseline in Body Mass Index (BMI) at Week 48 | Baseline, Week 48 |
| Pharmacokinetics (PK): Area Under the Curve (AUC) of Eloralintide at Steady State | Predose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 36; Post dose (2 to 6 hours after dosing) at Week 0, Week 24; Post dose (24 to 72 hours after dosing) at Week 12; random at Week 48 |
| PK: Maximum Concentration (Cmax) of Eloralintide at Steady State | Predose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 36; Post dose (2 to 6 hours after dosing) at Week 0, Week 24; Post dose (24 to 72 hours after dosing) at Week 12; random at Week 48 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT06230523.
Week 48 weight change posted for each eloralintide group
The posted primary outcome is the percent change from baseline in body weight at week 48.[1]
Outcome group OG004 is labelled 9 mg Eloralintide.[1]
The placebo group posted a least-squares mean change of -0.4%, with a spread of 0.91.[1]
Outcome group OG004 posted a least-squares mean change of -20.1%, with a spread of 1.31.[1]
Sources
- 1A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.